Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Abstract Background Breast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen receptor expression level and treatment effect are limited, particularly regarding chemotherapy benefit. We evaluated the pathologic response to...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Hai-long Chen, Feng-bo Huang, Qiang Chen, Yong-chuan Deng
Fformat:	Erthygl
Iaith:	English
Cyhoeddwyd:	BMC 2023-09-01
Cyfres:	BMC Cancer
Pynciau:	Breast cancer Estrogen receptor Neoadjuvant chemotherapy Pathologic complete response Prognosis
Mynediad Ar-lein:	https://doi.org/10.1186/s12885-023-11368-2

Eitemau Tebyg

Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
gan: He Dou, et al.
Cyhoeddwyd: (2024-01-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
gan: I.P.C. Buzatto, et al.

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
gan: Yingbo Shao, et al.
Cyhoeddwyd: (2025-03-01)

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
gan: Yingbo Shao, et al.
Cyhoeddwyd: (2024-02-01)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
gan: Jin Hong, et al.
Cyhoeddwyd: (2021-11-01)

Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
gan: Lingfeng Tang, et al.
Cyhoeddwyd: (2024-05-01)

A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer
gan: Shan Fang, et al.
Cyhoeddwyd: (2024-02-01)

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
gan: Zhendong Shi, et al.
Cyhoeddwyd: (2024-07-01)

Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma
gan: Yoshitaka Shimamaki, et al.
Cyhoeddwyd: (2024-02-01)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
gan: Mengping Long, et al.
Cyhoeddwyd: (2022-12-01)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
gan: Elina Sivina, et al.
Cyhoeddwyd: (2023-03-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
gan: Shuling Zhou, et al.
Cyhoeddwyd: (2023-02-01)

Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
gan: Ling-Ming Tseng, et al.
Cyhoeddwyd: (2023-12-01)

Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study
gan: Zhaoyue Zhou, et al.
Cyhoeddwyd: (2023-01-01)

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
gan: Mina M. G. Youssef, et al.
Cyhoeddwyd: (2021-02-01)

Short- and long-term outcomes of neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an updated meta-analysis
gan: Yue Guo, et al.
Cyhoeddwyd: (2025-02-01)

Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
gan: Cui Jiang, et al.
Cyhoeddwyd: (2019-09-01)

Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer
gan: Zuhat Urakçı, et al.
Cyhoeddwyd: (2023-10-01)

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
gan: Witali Aswolinskiy, et al.
Cyhoeddwyd: (2023-11-01)

Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy
gan: Li-Yun Xie, et al.
Cyhoeddwyd: (2022-04-01)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
gan: Lingfeng Tang, et al.
Cyhoeddwyd: (2022-12-01)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
gan: Ruo-Xi Wang, et al.
Cyhoeddwyd: (2022-10-01)

Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis
gan: Samuel Rosner, MD, et al.
Cyhoeddwyd: (2022-09-01)

Imaging‐proteomic analysis for prediction of neoadjuvant chemotherapy responses in patients with breast cancer
gan: Jingxian Duan, et al.
Cyhoeddwyd: (2023-12-01)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
gan: Jung Hwan Ji, et al.
Cyhoeddwyd: (2023-01-01)

Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China
gan: Shaorong Zhao, et al.
Cyhoeddwyd: (2024-05-01)

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB
gan: Pingping Liu, et al.
Cyhoeddwyd: (2022-04-01)

Accuracy of core biopsy image-guided post-neoadjuvant chemotherapy breast to predict pathologic complete response
gan: P. V. Krivorotko, et al.
Cyhoeddwyd: (2022-12-01)

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
gan: WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng
Cyhoeddwyd: (2023-07-01)

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
gan: Yanhua Chen, et al.
Cyhoeddwyd: (2020-03-01)

Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy
gan: Yushi Liu, et al.
Cyhoeddwyd: (2022-06-01)

A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012)
gan: Amina Maimaitiaili, et al.
Cyhoeddwyd: (2024-05-01)

Construction of a nomogram prediction model for the pathological complete response after neoadjuvant chemotherapy in breast cancer: a study based on ultrasound and clinicopathological features
gan: Pingjuan Ni, et al.
Cyhoeddwyd: (2025-03-01)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
gan: Lucas MW, et al.
Cyhoeddwyd: (2022-08-01)

Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model
gan: Xiaodan Feng, et al.
Cyhoeddwyd: (2025-02-01)

The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
gan: Sedat Yildirim, et al.
Cyhoeddwyd: (2024-05-01)

Extraction parameter optimized radiomics for neoadjuvant chemotherapy response prognosis in advanced nasopharyngeal carcinoma
gan: Yiling Wang, et al.
Cyhoeddwyd: (2022-03-01)

The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
gan: Eva L. Claassens, et al.
Cyhoeddwyd: (2025-04-01)

Impact of pathological complete response on survival in gastric cancer after neoadjuvant chemotherapy: a propensity score matching analysis
gan: Yonghe Chen, et al.
Cyhoeddwyd: (2025-01-01)

Radiomic model based on magnetic resonance imaging for predicting pathological complete response after neoadjuvant chemotherapy in breast cancer patients
gan: Yimiao Yu, et al.
Cyhoeddwyd: (2024-01-01)